Breaking News

Cerner CEO responds to U.S. market share losses at ViVE

Not rendering correctly? View this email as a web page here.

Bloomberg: Court docs reveal J&J's role in prison tests comparing talc to asbestos

By Frank Vinluan Monday, March 7, 2022 6:19 PM

Research of Johnson & Johnson's baby powder included a prison study in which inmates, mostly Black men, were injected with asbestos. The study was intended to assess how asbestos's effects on the skin compare to talc, the key component of baby powder.

Read more »

With lung drug from Pfizer in hand, AN2 tests IPO waters in turbulent market

By Frank Vinluan Monday, March 7, 2022 4:18 PM

Two biotechs are braving the roiling financial markets to raise money for clinical trials. AN2 Therapeutics is preparing for a pivotal test of its boron-based drug candidate for a rare, chronic lung disease. Okyo Pharma also filed IPO paperwork as it looks to advance to the clinic with its dry eye disease drug.

Read more »

Now is our chance to design digital health for equity: Here's how we can do it

By Veeneta Lakhani Monday, March 7, 2022 2:54 PM

As we embrace breakthroughs in digital health, let's not cut, paste and proliferate the health equity issues of the offline world. We can only claim success when we measure who's engaging, who's not and why.

Read more »

How do we defeat tobacco? By treating it as a chronic condition

By Jennifer Marler Monday, March 7, 2022 2:00 PM

Getting patients to quit and remain tobacco-free requires ongoing treatment that's customized, flexible, easy to use, and free to the user. Primary care providers are well versed in the management of chronic, treatable conditions. It's time for primary care doctors to light the way toward getting patients to quit tobacco.

Read more »

Alpine Immune Sciences cancer drug trial placed on partial hold after patient death

By Frank Vinluan Monday, March 7, 2022 11:19 AM

The FDA placed a partial clinical hold on a Phase 1 study testing experimental Alpine Immune Sciences cancer drug davoceticept in combination with Merck cancer immunotherapy Keytruda. The partial hold does not affect a separate study testing the Alpine drug as a monotherapy.

Read more »

Amwell exec weighs in on findings of AMA report, best practices for delivering behavioral healthcare virtually

By Emma Bardin Monday, March 7, 2022 10:00 AM

The director of psychological services at Amwell said that the report from the American Medical Association entitled "Accelerating and Enhancing Behavioral Health Integration Through Digitally Enabled Care: Opportunities and Challenges" represent a solid starting point for engaging multiple stakeholders in this effort.

Read more »

Why sustainability is sound business for healthcare providers

By Carsten Gieren Monday, March 7, 2022 9:00 AM

By moving decisively to address waste, emissions and social inequality, organizations can turn sustainability into a competitive advantage. Here's how.

Read more »

   

No comments